After publication of this work [1], it has come to our attention
that there is an error in the author list of the initial
version of this manuscript; rather than Ernest J Lam,
the second author of the manuscript should be listed as
Ernest T Lam

Hariani, GD

Havener, T

Kwok, Pui-Yan

Kwok, PY

Lam, EJ

McLeod, HL

Motsinger-Reif, AA

Wagner, MJ

BMC Research Notes

PubMed

Gunjan D Hariani

Ernest J Lam

Tammy Havener

Pui-Yan Kwok

Howard L McLeod

Michael J Wagner

Alison A Motsinger-Reif

Springer - Publisher Connector

Application of next generation sequencing to CEPH cell lines to discover variants associated with FDA approved chemotherapeutics

Ernest T Lam

Crossref

Erratum to: Application of next generation sequencing to CEPH cell lines to discover variants associated with FDA approved chemotherapeutics

Background: The goal of this study was to perform candidate gene association with cytotoxicity of chemotherapeutics in cell line models through resequencing and discovery of rare and low frequency variants along with common variations. Here, an associatio

eScholarship - University of California

Hariani et al. BMC Research Notes 2014, 7:652
http://www.biomedcentral.com/1756-0500/7/652CORRECTION Open AccessCorrection: Application of next generation
sequencing to CEPH cell lines to discover variants
associated with FDA approved
chemotherapeutics
Gunjan D Hariani1, Ernest T Lam3, Tammy Havener4, Pui-Yan Kwok3, Howard L McLeod4,5, Michael J Wagner4 and
Alison A Motsinger-Reif1,2*Correction
After publication of this work [1], it has come to our at-
tention that there is an error in the author list of the ini-
tial version of this manuscript; rather than Ernest J Lam,
the second author of the manuscript should be listed as
Ernest T Lam.
We publish this correction to update the author list
with this information. The correct author list is as
follows:
Gunjan D Hariani, Ernest T Lam, Tammy Havener,
Pui-Yan Kwok, Howard L McLeod, Michael J Wagner
and Alison A Motsinger-Reif
This error was introduced during the final production
process and the editors of BMC Research Notes apolo-
gise for any inconvenience caused.
Author details
1Bioinformatics Research Center, North Carolina State University, 307 Ricks
Hall, 1 Lampe Dr, 27695 CB7566 Raleigh, NC, USA. 2Department of Statistics,
North Carolina State University, Raleigh, NC, USA. 3Cardiovascular Research
Institute, UCSF School of Medicine, San Francisco, CA, USA. 4Center for
Institute of Pharmacogenomics and Individualized Therapy, UNC Chapel Hill,
Chapel Hill, NC, USA. 5Moffitt Cancer Center, Tampa, FL, USA.
Received: 9 September 2014 Accepted: 10 September 2014
Published: 17 September 2014* Correspondence: motsinger@stat.ncsu.edu
1Bioinformatics Research Center, North Carolina State University, 307 Ricks
Hall, 1 Lampe Dr, 27695 CB7566 Raleigh, NC, USA
2Department of Statistics, North Carolina State University, Raleigh, NC, USA
© 2014 Hariani et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.Reference
1. Hariani GD, Lam EJ, Havener T, Kwok PY, McLeod HL, Wagner MJ,
Motsinger-Reif AA: Application of next generation sequencing to CEPH
cell lines to discover variants associated with FDA approved
chemotherapeutics. BMC Res Notes 2014, 7:360.
doi:10.1186/1756-0500-7-652
Cite this article as: Hariani et al.: Correction: Application of next
generation sequencing to CEPH cell lines to discover variants associated
with FDA approved chemotherapeutics. BMC Research Notes 2014 7:652.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submitLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,


Correction: Application of next generation sequencing to CEPH cell lines to discover variants associated with FDA approved chemotherapeutics

file:///data/core-remote/dit/data/Springer-OA/pdf/1ec/aHR0cDovL2xpbmsuc3ByaW5nZXIuY29tLzEwLjExODYvMTc1Ni0wNTAwLTctMzYwLnBkZg==.pdf

Application of next generation sequencing to CEPH cell lines to discover variants associated with FDA approved chemotherapeutics

Abstract

Similar works

Full text

Available Versions

Springer - Publisher Connector

Crossref

Crossref

eScholarship - University of California

Springer - Publisher Connector

Springer - Publisher Connector

Springer - Publisher Connector